New Delhi: Ranbaxy Laboratories Ltd has said that it has entered into an exclusive licensing agreement with US-based BioPro Pharmaceuticals Inc for marketing and distributing its drug ‘Gliadel Wafer´ used for treating brain tumor.
“The licensing agreement and subsequent launch approval, should enable Ranbaxy to further strengthen its position in the Oncology segment,” Ranbaxy Vice President & Regional Director Asia and CIS Sanjeev I. Dani said.
“We are pleased to bring this lifesaving, high technology product to Indian patients and are also working with BioPro to create productive relationship by complementing each other’s strengths,” he added.
The company has also received the import permission for marketing the USFDA approved drug ‘GLIADEL Wafer’in India, Ranbaxy said.
Gliadel Wafer is the only FDA-approved chemotherapeutic drug implant for use during surgical resection, providing localised delivery of chemotherapy directly into the cavity when a brain tumor is removed by surgery.
The product is manufactured by MGI Pharma and BioPro retains the marketing rights in some Asian countries including China, Hong Kong, Taiwan, Korea and India.